YB-1(Y盒结合蛋白1)是一种多功能的冷休克蛋白,与癌症的所有标志有关。YB-1蛋白水平升高与几种癌症的不良预后相关。包括乳腺癌(BC),在所有亚型中,它是总体生存率(OS)降低和无远处转移生存率的标志。YB-1也由不同的细胞类型分泌,并可能充当细胞外有丝分裂原;然而,分泌形式的YB-1(sYB-1)的病理意义尚不清楚。我们的目的是回顾性评估通过ELISA测量的YB-1血清与BC和骨转移(BM)患者的疾病特征和预后之间的关系。在我们的队列中,在22例(50%)患者血清中检测到sYB-1,并且与骨外转移的存在相关(p=0.044)。sYB-1阳性也与骨疾病进展加快相关(HR3.1,95%CI1.09-8.95,P=0.033),但在OS方面没有观察到显著差异,以及骨骼相关事件发生的时间。此外,sYB-1阳性患者的IL-6水平也较高,这是一种已知的破骨细胞诱导因子.因此,在BC和BM患者中检测到sYB-1可能表明肿瘤负荷较高,在骨骼和骨骼外位置,并且是骨骼疾病进展更快的生物标志物。
YB-1 (Y-box binding protein 1) is a multifunctional cold-shock protein that has been implicated in all hallmarks of cancer. Elevated YB-1 protein level was associated with poor prognosis in several types of cancers, including breast cancer (BC), where it is a marker of decreased overall survival (OS) and distant metastasis-free survival across all subtypes. YB-1 is also secreted by different cell types and may act as an extracellular mitogen; however the pathological implications of the secreted form of YB-1 (sYB-1) are unknown. Our purpose was to retrospectively evaluate the association between YB-1 measured by ELISA in serum and disease characteristics and outcomes in patients with BC and bone metastases (BM). In our cohort, sYB-1 was detected in the serum of 22 (50%) patients, and was associated with the presence of extra-bone metastases (p=0.044). Positive sYB-1 was also associated with faster bone disease progression (HR 3.1, 95% CI 1.09-8.95, P=0.033), but no significant differences were observed concerning OS, and time to development of skeletal-related events. Moreover, patients with positive sYB-1 also had higher levels of IL-6, a known osteoclastogenic inducer. Therefore, detection of sYB-1 in patients with BC and BM may indicate a higher tumor burden, in bone and extra-bone locations, and is a biomarker of faster bone disease progression.